, called INK-ATTAC. These mice produce a caspase enzyme specifically in cells that express the p16 Ink4a gene. The caspase can be activated by the injection of a drug; the activated caspase then triggers cell death, eliminating senescent cells in which it is expressed.
Baker and colleagues found that the elimination of p16
Ink4a -expressing cells increased lifespan, regardless of the sex or strain of mouse examined, and ameliorated a range of age-dependent, disease-related abnormalities, including kidney dysfunction and abnormalities in heart and fat tissue (Fig. 1) . The authors observed increased activity and exploratory behaviour and a decrease in the incidence of cataracts (although this improvement was strain-dependent). Senescent-cell removal also delayed the onset of cancer, without affecting the range of observed tumour types. Together, these findings suggest that the accumulation of p16
Ink4a
-expressing cells during normal ageing shortens healthspan.
The INK-ATTAC mouse is a powerful model with which to investigate the physiological relevance of senescence, but it is not without limitations. For instance, the model is assumed to selectively eliminate senescent cells -and although not all p16
Ink4a -expressing cells are necessarily senescent, the ATTAC transgene that produces the caspase seems to be expressed only in senescent cells. However, it could be that drug treatment kills only 'late senescence' cells 5 , which express high levels of p16 Ink4a and ATTAC, rather than triggering a more general elimination of senescence. Moreover, drug treatment does not kill some senescent cells, including immune cells called lymphocytes as well as liver and colon cells, which limits the reach of the model. An improved characterization of the cell types that are eliminated is needed to fully understand the basis of the extended healthspan of these animals.
Another caveat is that the inducible elimination of senescent cells requires twiceweekly, long-term injections into the abdomen. Males that were injected with a control solution rather than the drug typically had shorter lifespans than normal mice, perhaps because of this intensive treatment regime. More-sophisticated model animals, in which senescent cells can be ablated in different tissues at different times and without the need for repeated injections, would help to extend the current findings.
Although the ablation of senescent cells ameliorates some age-related defects, it has no effect on others, including declines in motor performance, muscle strength and memory. This could reflect limitations of the ATTAC model. However, it might also suggest that senescent cells are involved in the progression of only some diseases.
Why might eliminating just the few cells that are senescent have beneficial effects in a range of tissues? Baker and colleagues' analysis of the kidney might help to explain this observation and clarify why senescent cells can be so disruptive during ageing. A striking disease-associated change often arises in aged kidneys, in capillary networks called glomeruli. However, the authors observed senescence primarily in another cell type, the epithelial cells of the kidney tubules. This suggests that SASP components secreted by epithelial cells could be responsible for disease in the glomeruli.
A search for compounds that can selectively eliminate senescent cells is under way 6, 7 , and could be an important step in translating the findings of Baker and colleagues' study to combating diseases of ageing in humans. An alternative therapeutic approach could be to repress the SASP. Indeed, inhibition of JAK proteins, which mediate the actions of some cytokines (a type of signalling molecule), reduces the SASP and alleviates frailty in old mice 8 . Rapamycin, a drug that is used as an immuno suppressant in humans, also robustly extends mouse life span 9 and regulates the SASP 10, 11 . Thus, common therapeutic mechanisms acting on the SASP might underlie the beneficial effects of both rapamycin and senescent-cell ablation on lifespan and healthspan.
It is worth noting that senescence is a protective response that limits tissue scarring (fibrosis) and cancer. Cells that express senescence markers are also involved in wound healing. Interestingly, the current study suggests that, although ablating senescent cells impairs wound healing, in general it has limited negative effects, and the authors found no evidence for increased fibrosis or cancer development. Nonetheless, any future senescence-based therapies must take care to control for possible detrimental consequences. ■ 
Jesús Gil

PLASMA PHYSICS
Compact coupling for a two-stage accelerator
Injecting electrons that have been accelerated by a laser-powered plasma wave into a second plasma wave represents a two-step electron accelerator. With 100 such steps, collider applications become possible. See Letter p.190
B R I G I T T E C R O S
L aser-plasma acceleration is a means of accelerating electrons in a plasma -a fluid of positively and negatively charged particles -using electric fields that are 1,000 times stronger than those of conventional particle accelerators operating in a vacuum. However, despite major advances in the past few years, reliable laser-plasma accelerators have still not been built. On page 190 of this issue, Steinke et al. 1 describe a way in which the coupling of electron beams can be controlled with plasmas. The authors' achievement could lead to the development of laser-driven electron accelerators that can be scaled up to achieve energy gains on a par with those of today's particle accelerators. Such electron accelerators would fit on a tabletop, and could replace conventional machines at medical facilities, for instance.
Plasma waves -collective oscillations of electrons on a background of heavier, stationary ions -are intrinsic characteristics of plasmas. The oscillating electrons lead to a charge separation in the plasma wave that is associated with an electric field of up to several hundred gigavolts per metre. Plasma waves can be generated by the application of an intense, ultrashort laser pulse 2 ( Fig. 1) , which acts like a snow plough to expel electrons from the most intense regions of the plasma.
Depending on the laser intensity, plasma waves exist in either the quasilinear or the nonlinear regime (according to the wave equations that describe them). In the quasilinear case, plasma waves provide a periodic accelerating structure for injected particle beams (Fig. 1) . Alternatively, nonlinear interactions between the laser pulse and the plasma electrons during laser propagation cause the plasma waves to form spherical cavities 3 that can trap and accelerate a fraction of the plasma electrons. For example, electrons in plasmas are typically accelerated to energies in the 100-megaelectronvolt range across millimetre distances, for laser systems that have a maximum power of 30 terawatts (1 terawatt is 10 12 W). With the development of petawattclass (10 15 W) laser systems, acceleration in the nonlinear regime -extended to several centimetres by laser guiding -has generated multi-gigaelectronvolt electron bunches 4 . (For comparison, the Stanford Linear Accelerator Center in Menlo Park, California, produces electrons of 50 GeV over 3 km, whereas a plasma can achieve 4 5 GeV in about 10 cm.) To further increase the accelerated electron energy, a large electric field must be maintained over the longest possible distance (up to metres for the quasilinear regime). Lowering the density of the electrons in the plasma helps to reduce nonlinear effects and to increase the acceleration distance, provided that the laser intensity is maintained at the required level over the whole distance. This can be achieved by guiding the laser beam externally, using either a preformed plasma structure or a gasfilled capillary tube. However, the inter action between the laser and the plasma causes a transfer of the laser beam's energy to the plasma, leading to 'laser depletion'. This problem, and the limitation on acceleration distance, can be resolved by using several plasma stages in sequence. Supplying a fresh laser beam for each subsequent accelerating stage makes the process scalable in electron energy and repetition rate, with a reasonable amount (10-100 joules) of laser energy per beam.
Steinke et al. have combined an ensemble of state-of-the-art plasma designs to achieve what could potentially be developed into an all-plasma compact accelerator driven by lasers. For the first stage, they use the non linear regime to create the electron beam from a gas jet; the nonlinear regime is necessary because, in the quasilinear regime, no electrons from the plasma itself can be trapped and accelerated. The authors use the quasilinear regime for the second stage, at which the accelerated electrons from the first stage, having energies of 100 MeV, are injected. Notably, the authors' components for coupling the injected electrons with the plasma wave and for focusing the laser have been reduced from the metre scale to the centimetre scale, with their entire set-up being on a scale of 10 cm.
The novelty of their scheme relies on the use of plasmas for every key element of the accelerator: the electron source is produced when a laser pulse hits a jet of gas, which becomes ionized as a plasma and leads to an electron beam of short duration (typically 10 femtoseconds; 1 femtosecond is 10 −15 s); the electron beam is focused by a plasma lens that is produced by a column of plasma created by discharge inside a capillary (the magnetic field of the plasma lens symmetrically confines the electrons); and the electron beam is accelerated in a plasma wave that is driven by a pulsed laser beam focused with a plasma mirror (a mirror that reflects light above a threshold intensity at which the surface of the material is ionized). In contrast to previous experiments, two independent laser beams are used, driving two separate accelerating plasma stages. The consequence of using plasmas for each element is to maintain the overall compactness of the beamline, thus preserving the global accelerating electric field.
Although this experiment is a remarkable achievement, room for improvement remains. The electron beam was externally injected into the plasma wave and accelerated with a maximum energy gain of 100 MeV and a 3.5% charge-coupling efficiency (the fraction of charge at the entrance of the second stage that will be accelerated at the exit). Steinke and colleagues present simulations showing that the trapping efficiency of electrons in the plasma wave might be increased to 90% by, for example, injecting an electron beam with optimized proportions specifically into the accelerating and focusing regions of the plasma wave. This could be achieved by using an electron beam (in which the spread of the electrons' energy is smaller than that in Steinke and colleagues' experiments) that is focused on a spot of typically less than 10 μm, and coupling this with a plasma wave that is larger than the electron beam and that is excited by a laser with a uniform amplitude (guided in a way that prevents oscillations). An energy gain in the 10-GeV range would be expected for metre-scale plasmas, although plasma waveguides of this size are not currently available. In addition to the quality of the coupling of the electron bunch as it enters the plasma, its stability in the plasma wave must be controlled precisely in space and time as it is accelerated, to achieve a high-quality electron beam.
Although there is a long way to go before a laser-plasma accelerator with 100 stages can be built for collider applications, intermediateenergy accelerators in the 10-GeV range are a realistic possibility in the near future, as test facilities for accelerator physics and other applications. Numerous research and development activities are under way worldwide, including collective efforts 5 Figure 1 | Structure of a plasma wave. An initial laser pulse propagating through a plasma displaces electrons (not shown) in the plasma. These electrons can generate a plasma wave in the 'quasilinear' regime, in which the wave has oscillating electric fields (longitudinal component shown by solid black arrows, transverse component by dotted black arrows). Injected electrons in tune with the accelerating phase (blue; decelerating phases in red) of the longitudinal wave and with the focusing fields pointing away from the horizontal axis -that is, within the black oblong -will be focused and accelerated. Steinke and co-authors 1 show that such a plasma wave can accelerate an electron beam produced from a first-stage plasma accelerator. In principle, using more than two stages will further scale the energy gain.
